Merus Reports the First Patient Dosing in P-III (LiGeR-HN1) Study of Petosemtamab Plus Keytruda for 1L Treatment of R/M Head and Neck Squamous Cell Carcinoma (HNSCC)
Shots:
- Merus has dosed the first patient under P-III (LiGeR-HN1) clinical evaluation of petosemtamab in addition to Keytruda for HNSCC
- The P-III (LiGeR-HN1) study aims to assess the safety & efficacy of petosemtamab + Keytruda vs Keytruda as a 1L treatment of patients (n=~500) with PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma. 1EPs include ORR & OS while 2EPs are DoR & PFS
- Petosemtamab (MCLA-158) is a biclonics low-fucose IgG1 antibody targeting EGFR and LGR5. It possesses three mechanisms, inhibiting EGFR signaling, LGR5 binding for EGFR internalization & cancer cell degradation as well as improving ADCC and ADCP activity
Ref: Merus | Image: Merus
Related News:- Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
